Dr. Sax is a distinguished cardiovascular expert with a rich background in medicine, research, and pharmaceutical development. After earning his MD from Columbia University's College, Dr. Sax pursued extensive training and certification in Internal Medicine and Cardiovascular Diseases. He served as an Assistant Professor of Medicine and Assistant Director of the CCU at Cornell University Medical Center before joining Merck Research Laboratories in 1991. 

At Merck, Dr. Sax led the successful development of the antiplatelet agent AGGRASTATÒ and later took on significant leadership roles, including Head of Clinical Cardiovascular Research and roles on the Worldwide Business Strategy Teams for Hypertension & Heart Failure and Antiplatelet/Antithrombotic. His expertise led him to AstraZeneca in 2001 as Vice President for U.S. Clinical Research, where he oversaw global cardiovascular research programs. Dr. Sax's journey continued with Quintiles, where he served as Senior Vice President for Integrated Clinical Services and played a pivotal role in developing the Center for Integrated Drug Development. Through his advisory to Radyus, Dr. Sax continues to offer innovative solutions to improve pharmaceutical R&D efficiency, drawing from his extensive experience in cardiovascular research and drug development.